desvenlafaxine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4380 93413-62-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • desvenlafaxine
  • desvenlafaxine succinate
  • pristiq
  • DVS-233
  • desvenlafaxine fumarate
The exact mechanism of the antidepressant action of desvenlafaxine is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. Non-clinical studies have shown that desvenlafaxine is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI).
  • Molecular weight: 263.38
  • Formula: C16H25NO2
  • CLOGP: 2.68
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 2
  • TPSA: 43.70
  • ALOGS: -2.27
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 572 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 45 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 5.42 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 3.50 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.70 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 8.40 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Feb. 29, 2008 FDA WYETH PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product residue present 772.21 14.53 199 24197 3780 63460846
Drug withdrawal syndrome 652.65 14.53 280 24116 26914 63437712
Suicidal ideation 375.23 14.53 256 24140 62165 63402461
Withdrawal syndrome 306.81 14.53 151 24245 19846 63444780
Feeling abnormal 292.16 14.53 321 24075 148071 63316555
Crying 281.90 14.53 150 24246 23193 63441433
Anxiety 246.43 14.53 357 24039 217184 63247442
Irritability 216.84 14.53 141 24255 31553 63433073
Insomnia 212 14.53 331 24065 214921 63249705
Dizziness 157.79 14.53 440 23956 429485 63035141
Anger 147.39 14.53 79 24317 12377 63452249
Nausea 136.47 14.53 667 23729 853804 62610822
Hyperhidrosis 116.03 14.53 173 24223 107663 63356963
Headache 107.00 14.53 503 23893 632738 62831888
Panic attack 102.84 14.53 78 24318 22253 63442373
Tremor 101.37 14.53 182 24214 132057 63332569
Nervousness 100.07 14.53 88 24308 30891 63433735
Depression 98.85 14.53 227 24169 196265 63268361
Agitation 98.30 14.53 118 24278 59639 63404987
Emotional disorder 90.18 14.53 59 24337 13320 63451306
Intentional product misuse 86.90 14.53 112 24284 60805 63403821
Condition aggravated 85.72 14.53 343 24053 401874 63062752
Abnormal dreams 84.94 14.53 52 24344 10464 63454162
Completed suicide 75.09 14.53 170 24226 145503 63319123
Feeling jittery 73.43 14.53 52 24344 13351 63451275
Contraindicated product administered 70.78 14.53 3 24393 217645 63246981
Suicide attempt 68.74 14.53 100 24296 60818 63403808
Thinking abnormal 67.04 14.53 45 24351 10598 63454028
Nightmare 64.95 14.53 56 24340 19138 63445488
Persistent genital arousal disorder 58.86 14.53 15 24381 271 63464355
Synovitis 53.59 14.53 5 24391 186913 63277713
Depressed mood 52.82 14.53 71 24325 40120 63424506
Overdose 52.41 14.53 128 24268 114950 63349676
Serotonin syndrome 51.05 14.53 59 24337 28623 63436003
Systemic lupus erythematosus 49.55 14.53 10 24386 208908 63255718
Disturbance in attention 49.48 14.53 67 24329 38122 63426504
Product substitution issue 48.78 14.53 44 24352 15952 63448674
Seizure 48.60 14.53 136 24260 132498 63332128
Pyrexia 47.55 14.53 67 24329 470411 62994215
Middle insomnia 47.12 14.53 39 24357 12604 63452022
Impaired driving ability 46.15 14.53 26 24370 4485 63460141
Drug ineffective 45.03 14.53 604 23792 1044161 62420465
Joint swelling 43.76 14.53 37 24359 327629 63136997
Pre-existing condition improved 42.89 14.53 31 24365 8213 63456413
Drug screen positive 42.87 14.53 23 24373 3606 63461020
Paraesthesia 42.65 14.53 145 24251 156821 63307805
Maternal exposure during pregnancy 42.02 14.53 16 24380 220046 63244580
Mania 41.67 14.53 36 24360 12331 63452295
Vision blurred 41.58 14.53 102 24294 91822 63372804
Migraine 40.87 14.53 109 24287 103237 63361389
Mydriasis 40.68 14.53 35 24361 11921 63452705
Acute kidney injury 40.00 14.53 26 24370 263389 63201237
Anorgasmia 39.59 14.53 13 24383 590 63464036
Tinnitus 39.47 14.53 58 24338 35570 63429056
Pericarditis 39.13 14.53 3 24393 131576 63333050
Blood pressure increased 39.12 14.53 144 24252 161918 63302708
Stomatitis 39.00 14.53 4 24392 138721 63325905
Dissociation 38.75 14.53 20 24376 2899 63461727
Somnolence 38.40 14.53 153 24243 178532 63286094
Anaemia 38.12 14.53 34 24362 293396 63171230
Bruxism 37.93 14.53 21 24375 3504 63461122
Coma scale abnormal 37.87 14.53 24 24372 5129 63459497
General physical health deterioration 37.86 14.53 15 24381 201387 63263239
Therapeutic response unexpected 37.50 14.53 41 24355 18718 63445908
Treatment failure 37.13 14.53 15 24381 199028 63265598
Energy increased 36.98 14.53 19 24377 2728 63461898
Aggression 34.74 14.53 44 24352 23454 63441172
Drug screen false positive 34.72 14.53 13 24383 871 63463755
Neutropenia 34.63 14.53 12 24384 174993 63289633
Mood altered 34.42 14.53 35 24361 14708 63449918
Arthropathy 33.22 14.53 25 24371 234767 63229859
Restlessness 32.70 14.53 48 24348 29405 63435221
Rheumatoid arthritis 32.26 14.53 30 24366 253789 63210837
Yawning 32.20 14.53 13 24383 1067 63463559
Lower respiratory tract infection 32.06 14.53 6 24390 132301 63332325
Paranoia 31.50 14.53 30 24366 11649 63452977
Infusion related reaction 31.22 14.53 29 24367 245492 63219134
Weight increased 30.65 14.53 188 24208 260604 63204022
Thrombocytopenia 30.54 14.53 10 24386 151147 63313479
Mood swings 29.92 14.53 36 24360 18212 63446414
Death 29.81 14.53 62 24334 374319 63090307
Peripheral swelling 29.78 14.53 35 24361 265907 63198719
Palpitations 29.59 14.53 103 24293 112667 63351959
Tachyphrenia 29.18 14.53 13 24383 1361 63463265
Mental disorder 28.43 14.53 42 24354 25877 63438749
Abnormal behaviour 28.37 14.53 38 24358 21388 63443238
Drug hypersensitivity 28.15 14.53 210 24186 310477 63154149
Euphoric mood 26.86 14.53 19 24377 4868 63459758
Stress 26.70 14.53 71 24325 67096 63397530
Wound 26.32 14.53 15 24381 163248 63301378
Libido decreased 26.26 14.53 15 24381 2657 63461969
Swelling 26.03 14.53 41 24355 275337 63189289
Nonspecific reaction 25.61 14.53 14 24382 2278 63462348
Amnesia 25.46 14.53 62 24334 55523 63409103
Glossodynia 25.36 14.53 19 24377 178857 63285769
Hostility 25.35 14.53 13 24383 1859 63462767
Hypersensitivity vasculitis 24.97 14.53 17 24379 4095 63460531
Infection 24.76 14.53 31 24365 229142 63235484
Panic reaction 24.74 14.53 17 24379 4157 63460469
Sympathomimetic effect 24.59 14.53 6 24390 90 63464536
Bipolar disorder 24.47 14.53 22 24374 7938 63456688
Unevaluable event 24.27 14.53 58 24338 51328 63413298
Tardive dyskinesia 23.23 14.53 22 24374 8480 63456146
Loss of libido 23.13 14.53 11 24385 1338 63463288
Wrong technique in product usage process 22.88 14.53 64 24332 62276 63402350
Apathy 22.60 14.53 22 24374 8772 63455854
Impaired healing 22.13 14.53 6 24390 102536 63362090
Febrile neutropenia 21.96 14.53 9 24387 118440 63346186
Hallucination 21.84 14.53 58 24338 54759 63409867
Post-traumatic stress disorder 21.25 14.53 17 24379 5234 63459392
Abdominal discomfort 20.90 14.53 59 24337 320826 63143800
Obsessive-compulsive disorder 20.51 14.53 15 24381 4045 63460581
Negative thoughts 20.42 14.53 9 24387 918 63463708
Tearfulness 20.26 14.53 15 24381 4124 63460502
Sepsis 19.55 14.53 18 24378 153105 63311521
Hepatic enzyme increased 19.23 14.53 30 24366 202298 63262328
Hallucination, auditory 18.93 14.53 24 24372 12800 63451826
Brain injury 18.82 14.53 18 24378 7025 63457601
Suicidal behaviour 18.67 14.53 12 24384 2627 63461999
Drug intolerance 18.48 14.53 59 24337 308602 63156024
Malaise 18.36 14.53 242 24154 415712 63048914
Alopecia 17.87 14.53 68 24328 337468 63127158
Pneumonia 17.73 14.53 103 24293 456664 63007962
Muscle twitching 17.57 14.53 29 24367 19639 63444987
Memory impairment 17.56 14.53 83 24313 104175 63360451
Restless legs syndrome 17.47 14.53 28 24368 18503 63446123
Product prescribing error 17.38 14.53 34 24362 26255 63438371
Intestinal pseudo-obstruction 17.38 14.53 8 24388 904 63463722
Arthralgia 17.37 14.53 138 24258 569572 62895054
Hypertensive emergency 16.99 14.53 10 24386 1872 63462754
Drug dependence 16.59 14.53 32 24364 24451 63440175
Decreased interest 16.39 14.53 12 24384 3242 63461384
Therapeutic response changed 16.34 14.53 8 24388 1037 63463589
Blood triglycerides increased 16.31 14.53 22 24374 12466 63452160
Impatience 16.27 14.53 6 24390 385 63464241
Wrong strength 16.27 14.53 4 24392 62 63464564
Malabsorption 16.09 14.53 13 24383 4059 63460567
Wernicke-Korsakoff syndrome 15.98 14.53 4 24392 67 63464559
Renal impairment 15.91 14.53 7 24389 88348 63376278
Feeling drunk 15.90 14.53 13 24383 4129 63460497
Galactorrhoea 15.86 14.53 13 24383 4142 63460484
Change in seizure presentation 15.82 14.53 6 24390 417 63464209
Discomfort 15.72 14.53 25 24371 167349 63297277
Pain 15.66 14.53 196 24200 740432 62724194
Malignant neoplasm progression 15.61 14.53 6 24390 82115 63382511
Dyspnoea 15.52 14.53 171 24225 661142 62803484
Ill-defined disorder 15.50 14.53 6 24390 81749 63382877
Coma 15.41 14.53 3 24393 64361 63400265
Aerophagia 15.40 14.53 3 24393 14 63464612
Insulinoma 15.17 14.53 4 24392 83 63464543
Major depression 15.12 14.53 17 24379 8001 63456625
Affect lability 15.10 14.53 20 24376 11131 63453495
Vertigo 15.09 14.53 54 24342 59833 63404793
Disease progression 15.01 14.53 15 24381 122743 63341883
Sleep-related eating disorder 14.77 14.53 7 24389 844 63463782
Impaired work ability 14.59 14.53 25 24371 17450 63447176

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product residue present 228.17 22.39 61 6812 2685 34947373
Serotonin syndrome 184.02 22.39 86 6787 19847 34930211
Drug withdrawal syndrome 166.01 22.39 80 6793 19754 34930304
Suicidal ideation 124.88 22.39 85 6788 40303 34909755
Anxiety 100.18 22.39 110 6763 99318 34850740
Suicide attempt 73.22 22.39 61 6812 39055 34911003
Hyperhidrosis 73.15 22.39 82 6791 75610 34874448
Overdose 70.39 22.39 88 6785 90971 34859087
Sexual dysfunction 57.48 22.39 27 6846 6276 34943782
Major depression 55.77 22.39 24 6849 4548 34945510
Feeling abnormal 55.15 22.39 65 6808 63170 34886888
Completed suicide 54.76 22.39 81 6792 98087 34851971
Insomnia 54.07 22.39 83 6790 103824 34846234
Withdrawal syndrome 50.20 22.39 31 6842 12424 34937634
Anger 48.97 22.39 30 6843 11854 34938204
Panic attack 41.93 22.39 25 6848 9407 34940651
Schizophreniform disorder 41.87 22.39 8 6865 72 34949986
Depression 40.23 22.39 70 6803 97028 34853030
Thinking abnormal 40.23 22.39 21 6852 6116 34943942
Drug ineffective 39.18 22.39 185 6688 456566 34493492
Nervousness 37.63 22.39 26 6847 12580 34937478
Erectile dysfunction 34.13 22.39 30 6843 20607 34929451
Coma scale abnormal 32.98 22.39 16 6857 3992 34946066
Drug interaction 30.01 22.39 105 6768 225841 34724217
Crying 29.92 22.39 17 6856 5845 34944213
Mania 29.29 22.39 20 6853 9491 34940567
Tremor 28.45 22.39 55 6818 82532 34867526
Libido decreased 27.76 22.39 15 6858 4681 34945377
Irritability 27.73 22.39 29 6844 24661 34925397
Dizziness 27.68 22.39 100 6773 218421 34731637
Drug screen positive 27.30 22.39 14 6859 3929 34946129
Headache 26.42 22.39 93 6780 200542 34749516
Dry mouth 26.25 22.39 31 6842 30134 34919924
Abnormal behaviour 25.70 22.39 28 6845 24941 34925117
Emotional disorder 25.01 22.39 15 6858 5701 34944357
Drug screen false positive 24.22 22.39 8 6865 731 34949327
Paralysis 24.15 22.39 15 6858 6067 34943991
Condition aggravated 22.68 22.39 86 6787 192110 34757948
Bipolar disorder 22.47 22.39 12 6861 3657 34946401

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Withdrawal syndrome 287.74 14.44 140 20506 26714 79697028
Suicidal ideation 238.02 14.44 180 20466 76160 79647582
Drug withdrawal syndrome 237.42 14.44 134 20512 34584 79689158
Feeling abnormal 223.24 14.44 239 20407 158960 79564782
Product residue present 191.96 14.44 60 20586 3476 79720266
Anxiety 191.35 14.44 276 20370 248236 79475506
Crying 190.92 14.44 101 20545 22942 79700800
Serotonin syndrome 169.39 14.44 119 20527 44908 79678834
Irritability 134.79 14.44 100 20546 41044 79682698
Overdose 125.01 14.44 193 20453 184013 79539729
Anger 111.25 14.44 64 20582 17098 79706644
Completed suicide 110.96 14.44 215 20431 245552 79478190
Suicide attempt 109.93 14.44 121 20525 82811 79640931
Insomnia 99.30 14.44 205 20441 244965 79478777
Depression 88.62 14.44 182 20464 216608 79507134
Panic attack 84.13 14.44 61 20585 24155 79699587
Hyperhidrosis 84.08 14.44 145 20501 151347 79572395
Emotional disorder 81.04 14.44 49 20597 14338 79709404
Dizziness 80.95 14.44 309 20337 526132 79197610
Coma scale abnormal 68.93 14.44 37 20609 8641 79715101
Nervousness 66.86 14.44 61 20585 33354 79690388
Tremor 66.19 14.44 140 20506 169943 79553799
Persistent genital arousal disorder 65.01 14.44 15 20631 266 79723476
Headache 63.63 14.44 335 20311 653437 79070305
Nausea 61.32 14.44 440 20206 956756 78766986
Drug ineffective 59.81 14.44 480 20166 1080433 78643309
Intentional product misuse 59.33 14.44 96 20550 95069 79628673
Product substitution issue 59.17 14.44 46 20600 20210 79703532
Depressed mood 57.84 14.44 67 20579 48413 79675329
Drug hypersensitivity 54.78 14.44 186 20460 298730 79425012
Thinking abnormal 54.68 14.44 37 20609 13124 79710618
Major depression 54.25 14.44 32 20614 8948 79714794
Acute kidney injury 51.27 14.44 36 20610 519368 79204374
Nightmare 47.47 14.44 45 20601 25816 79697926
Abnormal dreams 47.21 14.44 32 20614 11380 79712362
Agitation 41.00 14.44 84 20562 99631 79624111
Impaired driving ability 39.98 14.44 22 20624 5393 79718349
Pre-existing condition improved 39.43 14.44 22 20624 5541 79718201
Dissociation 37.23 14.44 19 20627 4002 79719740
General physical health deterioration 36.22 14.44 13 20633 275225 79448517
Febrile neutropenia 35.78 14.44 8 20638 230991 79492751
Neutropenia 35.54 14.44 15 20631 287695 79436047
Anaemia 35.21 14.44 38 20608 444977 79278765
Feeling jittery 35.00 14.44 28 20618 12813 79710929
Thrombocytopenia 34.11 14.44 13 20633 265246 79458496
Schizophreniform disorder 33.86 14.44 8 20638 158 79723584
Mental disorder 33.60 14.44 41 20605 31261 79692481
Panic reaction 31.84 14.44 18 20628 4647 79719095
Pyrexia 31.44 14.44 82 20564 678627 79045115
Tinnitus 30.77 14.44 47 20599 44286 79679456
Mood altered 30.76 14.44 30 20616 17817 79705925
Migraine 30.56 14.44 69 20577 87424 79636318
Mania 30.18 14.44 30 20616 18230 79705512
Seizure 29.83 14.44 112 20534 188722 79535020
Therapeutic response unexpected 29.74 14.44 31 20615 19915 79703827
Abnormal behaviour 28.71 14.44 41 20605 36380 79687362
Tardive dyskinesia 28.71 14.44 23 20623 10548 79713194
Paranoia 28.61 14.44 30 20616 19402 79704340
Condition aggravated 28.29 14.44 224 20422 500900 79222842
Mood swings 28.05 14.44 30 20616 19850 79703892
Hostility 27.63 14.44 13 20633 2297 79721445
Disturbance in attention 27.32 14.44 48 20598 50753 79672989
Contraindicated product administered 25.32 14.44 5 20641 157533 79566209
Prescribed overdose 24.66 14.44 39 20607 37844 79685898
Frustration tolerance decreased 24.03 14.44 18 20628 7484 79716258
Synovitis 23.78 14.44 5 20641 150729 79573013
Yawning 23.78 14.44 10 20636 1356 79722386
Bipolar disorder 23.59 14.44 18 20628 7689 79716053
Memory impairment 23.55 14.44 73 20573 111661 79612081
Suicidal behaviour 23.45 14.44 13 20633 3234 79720508
Bruxism 23.41 14.44 14 20632 4012 79719730
Renal impairment 23.37 14.44 6 20640 157777 79565965
Hypersensitivity vasculitis 23.00 14.44 17 20629 6926 79716816
Drug effective for unapproved indication 22.87 14.44 16 20630 5985 79717757
Product dose omission issue 22.69 14.44 125 20521 247412 79476330
Drug dependence 22.55 14.44 39 20607 40730 79683012
Malignant neoplasm progression 22.53 14.44 4 20642 135986 79587756
Sepsis 22.42 14.44 22 20624 269406 79454336
Affect lability 21.44 14.44 20 20626 11239 79712503
Reversible cerebral vasoconstriction syndrome 21.42 14.44 12 20634 3045 79720697
Systemic lupus erythematosus 21.34 14.44 3 20643 121146 79602596
Sympathomimetic effect 21.15 14.44 5 20641 99 79723643
Multiple organ dysfunction syndrome 21.13 14.44 3 20643 120243 79603499
Renal failure 21.04 14.44 13 20633 200955 79522787
Aggression 21.02 14.44 43 20603 50915 79672827
Drug interaction 20.94 14.44 181 20465 415002 79308740
Product dispensing error 20.47 14.44 21 20625 13242 79710500
Drug screen positive 20.43 14.44 15 20631 6048 79717694
Malaise 19.93 14.44 204 20442 489665 79234077
Hypersomnia 19.70 14.44 27 20619 23059 79700683
Stress 19.62 14.44 55 20591 79557 79644185
Self-injurious ideation 19.48 14.44 12 20634 3626 79720116
Toxicity to various agents 19.32 14.44 180 20466 421360 79302382
Palpitations 19.08 14.44 74 20572 126536 79597206
False positive investigation result 18.89 14.44 8 20638 1104 79722638
Bradycardia 18.52 14.44 6 20640 135551 79588191
Wrong strength 18.18 14.44 5 20641 184 79723558
Paraesthesia 18.17 14.44 92 20554 176231 79547511
Energy increased 18.02 14.44 11 20635 3271 79720471
Therapeutic response changed 17.68 14.44 8 20638 1293 79722449
Septic shock 17.56 14.44 5 20641 122796 79600946
Wernicke-Korsakoff syndrome 17.39 14.44 4 20642 70 79723672
Mental impairment 17.37 14.44 23 20623 19013 79704729
Hypertensive emergency 17.02 14.44 10 20636 2775 79720967
Amnesia 16.97 14.44 45 20601 63012 79660730
Ankyloglossia congenital 16.95 14.44 3 20643 12 79723730
Change in seizure presentation 16.90 14.44 6 20640 516 79723226
Tachyphrenia 16.89 14.44 9 20637 2071 79721671
Emotional distress 16.81 14.44 34 20612 39935 79683807
Impaired work ability 16.77 14.44 23 20623 19658 79704084
Ejaculation disorder 16.71 14.44 6 20640 533 79723209
Impulsive behaviour 16.65 14.44 10 20636 2890 79720852
Dysphoria 16.61 14.44 12 20634 4722 79719020
Joint swelling 16.50 14.44 31 20615 288615 79435127
Somnolence 16.40 14.44 112 20534 238869 79484873
Obsessive-compulsive disorder 16.32 14.44 13 20633 5914 79717828
Vertigo 16.32 14.44 47 20599 69035 79654707
Blood pressure orthostatic 16.27 14.44 4 20642 94 79723648
Hypotension 16.21 14.44 59 20587 440258 79283484
Stomatitis 16.05 14.44 9 20637 146748 79576994
Death 15.95 14.44 84 20562 566430 79157312
Hyperkalaemia 15.74 14.44 5 20641 114393 79609349
Brain injury 15.58 14.44 17 20629 11500 79712242
Lower respiratory tract infection 15.52 14.44 7 20639 129213 79594529
C-reactive protein increased 15.48 14.44 7 20639 129020 79594722
Paralysis 15.35 14.44 18 20628 13159 79710583
Dyspnoea 15.34 14.44 145 20501 856880 78866862
Insulinoma 15.09 14.44 4 20642 128 79723614
Intestinal pseudo-obstruction 14.98 14.44 9 20637 2600 79721142
Anorgasmia 14.82 14.44 7 20639 1247 79722495
Blood pressure increased 14.46 14.44 99 20547 211261 79512481

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06AX23 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Other antidepressants
FDA MoA N0000000102 Norepinephrine Uptake Inhibitors
FDA MoA N0000000109 Serotonin Uptake Inhibitors
MeSH PA D000928 Antidepressive Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D011619 Psychotropic Drugs
MeSH PA D000068760 Serotonin and Noradrenaline Reuptake Inhibitors
FDA EPC N0000175749 Serotonin and Norepinephrine Reuptake Inhibitor
FDA MoA N0000182137 Cytochrome P450 2D6 Inhibitors
CHEBI has role CHEBI:35469 antidepressants
CHEBI has role CHEBI:49103 drug metabolites
CHEBI has role CHEBI:83399 marine xenobiotic metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Major depressive disorder indication 370143000
Generalized anxiety disorder off-label use 21897009 DOID:14320
Social phobia off-label use 25501002 DOID:11257
Menopausal flushing off-label use 198436008
Neuropathic pain off-label use 247398009
Panic disorder off-label use 371631005 DOID:594
Ocular hypertension contraindication 4210003 DOID:9282
Suicidal thoughts contraindication 6471006
Hypercholesterolemia contraindication 13644009
Bipolar disorder contraindication 13746004 DOID:3312
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Hypertensive disorder contraindication 38341003 DOID:10763
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Syndrome of inappropriate vasopressin secretion contraindication 55004003 DOID:3401
Cerebrovascular disease contraindication 62914000 DOID:6713
Blood coagulation disorder contraindication 64779008 DOID:1247
Hyponatremia contraindication 89627008
Seizure disorder contraindication 128613002
Bleeding contraindication 131148009
Impaired renal function disorder contraindication 197663003
Mania contraindication 231494001
Hypomania contraindication 231496004
Interstitial lung disease contraindication 233703007 DOID:3082
Disease of liver contraindication 235856003 DOID:409
Hypertriglyceridemia contraindication 302870006
Serotonin syndrome contraindication 371089000
Angle-closure glaucoma contraindication 392291006 DOID:13550
Myocardial infarction in recovery phase contraindication 418044006
Hypertensive urgency contraindication 443482000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.79 acidic
pKa2 9.33 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 7.33 WOMBAT-PK CHEMBL
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Ki 6.28 WOMBAT-PK CHEMBL
Alpha-1A adrenergic receptor GPCR IC50 7.22 CHEMBL

External reference:

IDSource
D07793 KEGG_DRUG
4027338 VUID
N0000176142 NUI
386750-22-7 SECONDARY_CAS_RN
4027338 VANDF
C1880288 UMLSCUI
CHEBI:83527 CHEBI
CHEMBL1118 ChEMBL_ID
CHEMBL1201728 ChEMBL_ID
DB06700 DRUGBANK_ID
7158 IUPHAR_LIGAND_ID
8361 INN_ID
93414-04-1 SECONDARY_CAS_RN
NG99554ANW UNII
125017 PUBCHEM_CID
683693 RXNORM
132507 MMSL
200628 MMSL
25184 MMSL
339716 MMSL
38906 MMSL
d07113 MMSL
012574 NDDF
012575 NDDF
015249 NDDF
430267008 SNOMEDCT_US
430271006 SNOMEDCT_US
433292007 SNOMEDCT_US
D000069468 MESH_DESCRIPTOR_UI
CHEMBL3989861 ChEMBL_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Pristiq Extended-Release HUMAN PRESCRIPTION DRUG LABEL 1 0008-1210 TABLET, EXTENDED RELEASE 25 mg ORAL NDA 31 sections
Pristiq Extended-Release HUMAN PRESCRIPTION DRUG LABEL 1 0008-1210 TABLET, EXTENDED RELEASE 25 mg ORAL NDA 31 sections
Pristiq Extended-Release HUMAN PRESCRIPTION DRUG LABEL 1 0008-1210 TABLET, EXTENDED RELEASE 25 mg ORAL NDA 31 sections
Pristiq Extended-Release HUMAN PRESCRIPTION DRUG LABEL 1 0008-1211 TABLET, EXTENDED RELEASE 50 mg ORAL NDA 31 sections
Pristiq Extended-Release HUMAN PRESCRIPTION DRUG LABEL 1 0008-1211 TABLET, EXTENDED RELEASE 50 mg ORAL NDA 31 sections
Pristiq Extended-Release HUMAN PRESCRIPTION DRUG LABEL 1 0008-1211 TABLET, EXTENDED RELEASE 50 mg ORAL NDA 31 sections
Pristiq Extended-Release HUMAN PRESCRIPTION DRUG LABEL 1 0008-1222 TABLET, EXTENDED RELEASE 100 mg ORAL NDA 31 sections
Pristiq Extended-Release HUMAN PRESCRIPTION DRUG LABEL 1 0008-1222 TABLET, EXTENDED RELEASE 100 mg ORAL NDA 31 sections
Pristiq Extended-Release HUMAN PRESCRIPTION DRUG LABEL 1 0008-1222 TABLET, EXTENDED RELEASE 100 mg ORAL NDA 31 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 0054-0400 TABLET, FILM COATED, EXTENDED RELEASE 50 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 0054-0400 TABLET, FILM COATED, EXTENDED RELEASE 50 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 0054-0401 TABLET, FILM COATED, EXTENDED RELEASE 100 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 0054-0401 TABLET, FILM COATED, EXTENDED RELEASE 100 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 0054-0603 TABLET, FILM COATED, EXTENDED RELEASE 25 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 0054-0603 TABLET, FILM COATED, EXTENDED RELEASE 25 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 0591-3659 TABLET, EXTENDED RELEASE 50 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 0591-3659 TABLET, EXTENDED RELEASE 50 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 0591-3660 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 0591-3660 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 0591-4060 TABLET, EXTENDED RELEASE 25 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 0591-4060 TABLET, EXTENDED RELEASE 25 mg ORAL ANDA 30 sections
Desvenlafaxine Human Prescription Drug Label 1 35208-009 TABLET, EXTENDED RELEASE 50 mg ORAL ANDA 30 sections
Desvenlafaxine Human Prescription Drug Label 1 35208-010 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 30 sections
PristiqExtended-Release HUMAN PRESCRIPTION DRUG LABEL 1 43063-262 TABLET, EXTENDED RELEASE 50 mg ORAL NDA 31 sections
Desvenlafaxine Human Prescription Drug Label 1 46708-152 TABLET, EXTENDED RELEASE 50 mg ORAL NDA 30 sections
Desvenlafaxine Human Prescription Drug Label 1 46708-152 TABLET, EXTENDED RELEASE 50 mg ORAL NDA 30 sections
Desvenlafaxine Human Prescription Drug Label 1 46708-153 TABLET, EXTENDED RELEASE 100 mg ORAL NDA 30 sections
Desvenlafaxine Human Prescription Drug Label 1 46708-153 TABLET, EXTENDED RELEASE 100 mg ORAL NDA 30 sections
Desvenlafaxine Human Prescription Drug Label 1 46708-540 TABLET, EXTENDED RELEASE 50 mg ORAL ANDA 30 sections
Desvenlafaxine Human Prescription Drug Label 1 46708-540 TABLET, EXTENDED RELEASE 50 mg ORAL ANDA 30 sections